Norovirus – 2026
This Phase III clinical trial is designed to evaluate the safety, tolerability, and effectiveness of an investigational Norovirus vaccine candidate. The study seeks to determine if the vaccine can effectively prevent norovirus acute gastroenteritis (AGE) in a specific population group.
You can contact our office at 501-623-9930 or fill out the short "Do You Qualify" Questionnaire to see if you qualify for this study.
Qualifications and Compensation
- up to $1,000 for study related time and travel
Sign Up Form
Thank you
Your information has been submitted. We will contact you shortly, or please call (501) 623-9930 to inquire about your status.
